HF
ADMS

HRT Financial’s Adamas Pharmaceuticals ADMS Stock Holding History

HRT Financial’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,432
Closed -$43K – 1528
2019
Q4 		$43K Sell
11,432
-1,802
-14% -$8.63K ﹤0.01% 1072
2019
Q3 		$67K Buy
+13,234
New +$81.7K ﹤0.01% 1284

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's ADMS Position: Q1 2020 in Review

HRT Financial sold out of Adamas Pharmaceuticals (ADMS) in Q1 2020, closing a stake of 11,432 shares — an estimated $43K sold.

HRT Financial first reported a position in ADMS in Q3 2019 and held it in 2 quarters. The position peaked at $67K in Q3 2019. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2020.

  • HRT Financial reported no remaining Adamas Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • HRT Financial sold 11,432 Adamas Pharmaceuticals shares in Q1 2020, an estimated $43K.
  • HRT Financial first reported a position in Adamas Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • HRT Financial's Adamas Pharmaceuticals position peaked at $67K in Q3 2019.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2020.

Based on HRT Financial's 13F filing for Q1 2020, filed 15 May 2020.